A nationwide German study of prescription data has demonstrated that switching to an antiepileptic drug from a different manufacturer increases the risk of seizure relapse. This finding sparks a debate about the reason for seizure worsening after switching and whether or not it is a pharmacological issue.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lang, J. D. et al. Switching the manufacturer of anti-epileptic drugs is associated with higher risk of seizures. Ann. Neurol. https://doi.org/10.1002/ana.25353 (2018).
Davit, B. M. et al. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann. Pharmacother. 43, 1583–1597 (2009).
Krauss, G. L. et al. Assessing bioequivalence of generic antiepilepsy drugs. Ann. Neurol. 70, 221–228 (2011).
Labiner, D. M. et al. Generic antiepileptic drugs and associated medical resource utilization in the United States. Neurology 74, 1566–1574 (2010).
Andermann, F. et al. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia 48, 464–469 (2007).
Ting, T. J. et al. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: a field test of the FDA bioequivalence standard. Epilepsia 56, 1415–1424 (2015).
Privitera, M. D. et al. Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial. Lancet Neurol. 15, 365–372 (2016).
Gollwitzer, S. et al. Nonadherence to antiepileptic drugs in Germany: a retrospective, population-based study. Neurology 87, 466–472 (2016).
Kesselheim, A. S. et al. Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. JAMA Intern. Med. 173, 202–208 (2013).
Holtkamp, M. & Theodore, W. H. Generic antiepileptic drugs — safe or harmful in patients with epilepsy? Epilepsia 59, 1273–1281 (2018).
Acknowledgements
The author holds the Friedrich-von-Bodelschwingh Endowed Professorship for Clinical and Experimental Epileptology at the Department of Neurology, Charité–Universitätsmedizin Berlin funded by the v. Bodelschwingh Foundation. The funder had no influence on this work.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author has received speaker’s honoraria and/or consultancy fees from Bial, Desitin, Eisai, LivaNova, Novartis and UCB.
Rights and permissions
About this article
Cite this article
Holtkamp, M. How safe is switching antiepileptic drug manufacturers?. Nat Rev Neurol 15, 8–9 (2019). https://doi.org/10.1038/s41582-018-0108-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-018-0108-6